Research Reports | Market Assessment
December 2015

Malignant Melanoma | TreatmentTrends | US | 2015 (Q4)

This quarterly report series examines the current management of unresectable/metastatic malignant melanoma in the United States from the perspective of medical oncologists and explores trends in treatment practices. It enables a greater understanding of medical practice patterns in unresectable/metastatic malignant melanoma, segmented by BRAF-mutational status; of physicians’ perceptions of drug brands, including recently launched BRAF-targeted therapies and anti-PD-1 immunotherapies, and of specific product attributes; and of the impact of sales and brand messaging efforts.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports